Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BMS-986504 |
| Trade Name | |
| Synonyms | BMS 986504|BMS986504 |
| Drug Descriptions |
BMS-986504 binds to the PRMT5-MTA complex and inhibits PRMT5 activity, which potentially enhances antitumor immune response and induces killing of tumor cells with deletion of MTAP (Cancer Immunol Res (2024) 12 (10_Supplement): B011, Eur J Cancer 211 (2024): 114537). |
| DrugClasses | PRMT5 Inhibitor 21 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BMS-986504 | BMS-986504 | 0 | 3 |
| BMS-986504 + Gemcitabine + Nab-paclitaxel | BMS-986504 Gemcitabine Nab-paclitaxel | 0 | 1 |
| BMS-986504 + Pembrolizumab | BMS-986504 Pembrolizumab | 0 | 1 |